

ASX RELEASE

7 August 2024

GRANTING OF KEY CHEMICAL FORM PATENT IN EUROPE AND JAPAN

HIGHLIGHTS

- *A key patent for the company's best-in-class FAK inhibitor narmafotinib has been granted in Japan and Europe.*
- *Patent protection for narmafotinib now extends to at least 2040 in these markets.*

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce the granting of a key patent in Europe and Japan. The patent, entitled *A salt and crystal form of a FAK Inhibitor*, describes the specific chemical form of the company's best-in-class FAK inhibitor narmafotinib.

The Company has received notification from the Japanese Patent Office that the patent was granted in Japan on 18 July 2024, whilst the European Patent Office have advised that the patent will grant in Europe on 28 August 2024.

This patent describes a stable, manufacturable form of narmafotinib that provides improved drug levels upon dosing. Importantly, it is this specific form of the drug that is being developed clinically by the Company, including in the current Phase 2a ACCENT trial in advanced pancreatic cancer.

Amplia's CEO and Managing Director Dr Chris Burns comments: "The granting of this patent by two of the world's most respected patent offices bodes well for granting of the patent in other jurisdictions, including the US and Australia. Importantly from a commercial perspective, this patent extends protection for narmafotinib out to at least 2040."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer study, and is currently in an open-label Phase 2a trial in pancreatic cancer called the [ACCENT trial](#),

where a combination of narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety, tolerability and efficacy.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), [Threads](https://www.threads.net/@ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).